Clinically mild encephalopathy with a reversible splenial lesion and nonconvulsive status epilepticus in a schizophrenic patient with neuroleptic malignant syndrome

Taichi Mogi; Hiroyuki Toda; Yasutaka Tatsuzawa; Tsubasa Fukutomi; Shigeyoshi Soga; Hiroshi Shinmoto; Aihide Yoshino

doi:10.1111/pcn.12492

Clinically mild encephalopathy with a reversible splenial lesion and nonconvulsive status epilepticus in a schizophrenic patient with neuroleptic malignant syndrome

Taichi Mogi, Hiroyuki Toda, Yasutaka Tatsuzawa, Tsubasa Fukutomi, Shigeyoshi Soga, Hiroshi Shinmoto, Aihide Yoshino

研究成果: Letter › 査読

本文言語	English
ページ（範囲）	212
ページ数	1
ジャーナル	Psychiatry and Clinical Neurosciences
巻	71
号	3
DOI	https://doi.org/10.1111/pcn.12492
出版ステータス	Published - 2017 3月 1
外部発表	はい

ASJC Scopus subject areas

神経科学（全般）
神経学
臨床神経学
精神医学および精神衛生

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1111/pcn.12492

他のファイルとリンク

引用スタイル

@article{ae9e1d5971d64ef7b41bf4c6b6926e4c,

title = "Clinically mild encephalopathy with a reversible splenial lesion and nonconvulsive status epilepticus in a schizophrenic patient with neuroleptic malignant syndrome",

author = "Taichi Mogi and Hiroyuki Toda and Yasutaka Tatsuzawa and Tsubasa Fukutomi and Shigeyoshi Soga and Hiroshi Shinmoto and Aihide Yoshino",

note = "Funding Information: Dr Toda has received research/grant support from GlaxoSmithKline. The other authors have no conflicts of interest to declare.",

year = "2017",

month = mar,

day = "1",

doi = "10.1111/pcn.12492",

language = "English",

volume = "71",

pages = "212",

journal = "Psychiatry and Clinical Neurosciences",

issn = "1323-1316",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Clinically mild encephalopathy with a reversible splenial lesion and nonconvulsive status epilepticus in a schizophrenic patient with neuroleptic malignant syndrome

AU - Mogi, Taichi

AU - Toda, Hiroyuki

AU - Tatsuzawa, Yasutaka

AU - Fukutomi, Tsubasa

AU - Soga, Shigeyoshi

AU - Shinmoto, Hiroshi

AU - Yoshino, Aihide

N1 - Funding Information: Dr Toda has received research/grant support from GlaxoSmithKline. The other authors have no conflicts of interest to declare.

PY - 2017/3/1

Y1 - 2017/3/1

UR - http://www.scopus.com/inward/record.url?scp=85014444949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014444949&partnerID=8YFLogxK

U2 - 10.1111/pcn.12492

DO - 10.1111/pcn.12492

M3 - Letter

C2 - 27976828

AN - SCOPUS:85014444949

SN - 1323-1316

VL - 71

SP - 212

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

IS - 3

ER -